The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma.
C. Suarez
No relevant relationships to disclose
E. Gallardo
Honoraria - Pfizer
Other Remuneration - Pfizer
J. Rodon Ahnert
No relevant relationships to disclose
M. Guix
No relevant relationships to disclose
T. Bonfill
No relevant relationships to disclose
F. Pons
No relevant relationships to disclose
M. Beltran
No relevant relationships to disclose
I. Moya
Other Remuneration - Pfizer
S. Galtes
No relevant relationships to disclose
J. Albanell
Consultant or Advisory Role - Pfizer
J. Carles
No relevant relationships to disclose
J. Bellmunt
Consultant or Advisory Role - Pfizer